Phase 1/2 study of single‑agent Zanubrutinib in patients with relapsed / refractory marginal zone lymphoma

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

I am a Healthcare Professional from:

Phase 1/2 study of single‑agent Zanubrutinib in patients with relapsed / refractory marginal zone lymphoma

Rating

Rate this resource

Phase 1/2 study of single‑agent Zanubrutinib in patients with relapsed / refractory marginal zone lymphoma

Rating

Rate this resource

Related resources

Recent developments